《中国康复理论与实践》

《中国康复理论与实践》 ›› 2005, Vol. 11 ›› Issue (07): 580-581.

• 临床观察 • 上一篇    下一篇

神经节苷脂GM1在帕金森氏病症状波动治疗中的应用

高聪; 蒲蜀湘; 杨宁   

  1. 广州医学院第二附属医院神经内科 广东广州市 510260
  • 收稿日期:2005-04-04 出版日期:2005-07-25 发布日期:2005-07-25

Application of GM1 ganglioside in Parkinson's disease with motor fluctuations

GAO Cong, PU Shu-xiang, YANG Ning   

  1. Department of Neurology, the Second Hospital Affiliated to Guangzhou Medical College, Guangzhou 510260, Guangdong, China
  • Received:2005-04-04 Published:2005-07-25 Online:2005-07-25

PDF (PC)

摘要： 目的探讨神经节苷脂GM1治疗帕金森氏病(PD)的疗效和安全性。方法对33例长期服用左旋多巴等治疗帕金森氏病药物后出现症状波动的患者,加用神经节苷脂GM1 100mg/d,静脉滴注,每日1次,疗程4周。分别在GM1治疗后2、3、4周对患者进行帕金森病统一评分量表(UPDRS)运动评分及日常生活活动能力(ADL)评分,并观察治疗期间药物的毒副作用。结果33例PD患者在GM1治疗后2、3、4周UPDRS运动评分分别为(23.5±8.9)、(22.8±8.3)和(22.5±9.1),与治疗前(36.7±10.2)比较,均有非常显著性差异(P<0.01);ADL评分分别为(21.4±10.9)、(20.3±9.5)和(20.6±10.2),与治疗前(30.5±12.1)比较,亦均有非常显著性差异(P<0.01)。但治疗2、3、4周的UPDRS运动评分或ADL评分两两比较,无显著性差异(P>0.05)。治疗期间没有观察到明显的毒副作用。结论对长期服用左旋多巴出现症状波动或疗效减退的PD患者,加用GM1治疗,能在一定程度上改善患者的运动功能和日常生活能力。

关键词: 帕金森氏病, 左旋多巴, 神经节苷脂GM1

Abstract: ObjectiveTo evaluate the safety and efficacy of GM1 ganglioside treatment for persons with Parkinson's disease.Methods33 Parkinson's disease patients with a fluctuating response to levodopa received 100 mg GM1 ganglioside (used as add-on agent to the previous medication regimen) daily. Unified Parkinson's disease Rating scale (UPDRS) motor score and Activities of Daily Living (ADL) score were measure before and 2, 3 or 4 weeks after treatment. The side-effect of GM1 during treatment were observed. ResultsAfter 2, 3, 4 weeks of treatment, There was significant improvement in patients with GM1 treament on the UPDRS motor scores were (23.5±8.9), (22.8±8.3) and (22.5±9.1) respectively, which was improved compared with that before (36.7±10.2) (P<0.01). The ADL portion of the UPDRS at these time were (21.4±10.9), (20.3±9.5) and (20.6±10.2) respectively, also showed significant improvement compared with the baseline (30.5±12.1) (P<0.01). However, there was no significant differece between the scores that measured at the time spots 2 weeks after treatment.No side-effect had been observed.ConclusionGM1 ganglioside can improve neurologic function significantly in PD patients with fluctuating response to levodopa.

Key words: Parkinson's disease, levodopa, GM1 ganglioside